438 Studies Now Enrolling
A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON-SMALL CELL LUNG CANCER
Study of a New Treatment (Atezolizumab) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
| Sponsor: | Genentech, Inc. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR6740 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to compare the effects of atezolizumab, an immunotherapy drug, with chemotherapy or placebo with chemotherapy in patients with resectable NSCLC to find out which is better. In this study, you will receive treatment before undergoing surgery to remove the tumor.
This study is closed
Do You Qualify?
| Are you 18 years of age or older? | Yes | No |
| Do you have non-small cell lung cancer that can be surgically removed? | Yes | No |
| Have you received any treatment for your non-small cell lung cancer? | Yes | No |
| Are you willing to receive a platinum-chemotherapy as part of the clinical trial treatment? | Yes | No |